Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06015217 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT06015217: Completed Phase 4 study, sponsored by Galderma R&D.
NCT06015217 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06015217, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess the efficacy and safety of a Healing Ointment in infants 2-24 months with mild to moderate diaper rash. The main question it aims to answer is: • does a Healing Ointment improve skin texture and smoothness in infants with mild to moderate diaper dermatitis? Participants will use a Healing Ointment on the diaper area with every diaper change, have the Investigator perform efficacy and tolerability assessments, and complete questionnaires regarding subject satisfaction.
Primary Outcome
Product efficacy will be measured by Investigator's evaluation of visual skin texture. Skin texture was measured on a 10-point modified Griffith's scale, where 0 is the best possible condition and 9 is the worst possible condition.
Interventions
- DRUG "Cetaphil Healing Ointment"
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-08-25 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 4 |
What the finished NCT06015217 record still lists
NCT06015217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which "Cetaphil Healing Ointment" is the first listed.
NCT06015217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06015217 about?
NCT06015217 is a clinical study titled "A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash". The goal of this clinical trial is to assess the efficacy and safety of a Healing Ointment in infants 2-24 months with mild to moderate diaper rash. The main question it aims to answer is: • does a Healing Ointment improve skin texture and smoothness in infants with mild to moderate diaper dermatit...
What is the current status of trial NCT06015217?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2023-08-25. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT06015217?
The interventions under investigation include: "Cetaphil Healing Ointment" (DRUG).
Who is sponsoring clinical trial NCT06015217?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06015217's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI